Akoya Biosciences Inc Total Liabilities
Akoya Biosciences Inc total liabilities. Based on the latest financial reports, Akoya Biosciences Inc (AKYA) has total liabilities worth $118.54 Million USD as of March 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check AKYA asset liquidity ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Akoya Biosciences Inc (2019–2024)
Total liabilities of Akoya Biosciences Inc from 2019 to 2024. This chart illustrates how Akoya Biosciences Inc's total liabilities have evolved over time, based on quarterly financial data. Explore AKYA long-term investment intensity to see how much of total assets are deployed in long-term investments.
Akoya Biosciences Inc Competitors by Total Liabilities
The table below lists competitors of Akoya Biosciences Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Lixte Biotechnology Holdings Inc
NASDAQ:LIXT
|
USA | $1.69 Million |
|
Endava plc
F:2Y5
|
Germany | €362.92 Million |
|
artnet AG Namens-Aktien o.N.
XETRA:ART
|
Germany | €29.69 Million |
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $123.36 Million |
|
Macroblock
TWO:3527
|
Taiwan | NT$272.68 Million |
|
Sun Brothers Development Co Ltd
TWO:3489
|
Taiwan | NT$3.29 Billion |
|
Stillwater Critical Minerals Corp
V:PGE
|
Canada | CA$681.37K |
|
HY Energy Group Co Ltd
SHG:600387
|
China | CN¥924.38 Million |
Liability Composition Analysis (2019–2024)
This chart breaks down Akoya Biosciences Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see AKYA total asset value.
Liquidity & Leverage Metrics
Akoya Biosciences Inc Total Liabilities Ratios Explained
Akoya Biosciences Inc total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.61 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -20.13 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.05 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Akoya Biosciences Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Akoya Biosciences Inc (2019–2024)
The table below shows the annual total liabilities of Akoya Biosciences Inc from 2019 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $117.41 Million | -7.26% |
| 2023-12-31 | $126.60 Million | +7.79% |
| 2022-12-31 | $117.45 Million | +68.86% |
| 2021-12-31 | $69.56 Million | +17.71% |
| 2020-12-31 | $59.09 Million | -50.58% |
| 2019-12-31 | $119.57 Million | -- |
About Akoya Biosciences Inc
Akoya Biosciences, Inc., a life sciences technology company, provides spatial biology solutions for transforming discovery, clinical research, and diagnostics in North America, the Asia-Pacific, Europe, the Middle East, and Africa. The company offers PhenoCycler instrument, a compact bench-top fluidics system that integrates with a companion microscope to automate image acquisition; and PhenoImag… Read more